Print  |  Close

Mark A. Taylor MD

Mark A. Taylor MD

Summit Cancer Care

Education and Training

Medical School: Jefferson Medical College, Philadelphia, Pennsylvania

Internship: Emory University Affiliated Hospitals, Atlanta, Georgia

Residency: Emory University Affiliated Hospitals, Atlanta, Georgia

Fellowship: University of North Carolina, Chapel Hill, North Carolina

Specialty and Certification

Medical Oncology / Board Certified

Clinical Trial Cancer Types

Breast Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Leukemia, Lung Cancer, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian Cancer, Plasma cell neoplasm, Primary Peritoneal Cancer, Prostate Cancer , Quality of Life, Solid Tumor

Affiliations

St. Joseph's/Candler

Active Clinical Trial Sites in Georgia

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center

4700 Waters Avenue
Savannah, GA 31404
912-350-8490 (p)
www.memorialhealth.com/anderson-cancer-institute.aspx

driving directions

Clinical Trials


DeKalb Surgical Associates - Northside

980 Johnson Ferry Road, NE
Suite 430
Atlanta, GA 30342
404-508-4320 (p)
404-508-4112 (f)
www.dekalbsurgical.com

driving directions

Clinical Trials


Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Breast Cancer

Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Cancer Type: Breast Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer

Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cancer Type: Breast Cancer

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Colon/Rectal Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Leukemia

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Lung Cancer

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Lung Cancer

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type: Lung Cancer

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Lung Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type: Melanoma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Multiple Myeloma

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Plasma cell neoplasm

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Plasma cell neoplasm

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Prostate Cancer

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type: Solid Tumor

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Solid Tumor

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type: Solid Tumor

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Solid Tumor

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Solid Tumor

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Unknown Primary

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Unknown Primary

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Unknown Primary

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Unknown Primary

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Unknown Primary

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Unknown Primary

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Unknown Primary

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Unknown Primary

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Unknown Primary

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Unknown Primary

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Unknown Primary


Summit Cancer Care - Statesboro

16741 Highway 67 South
Suite B
Statesboro, GA 30458
912-871-8837 (p)
www.summitcancercare.com

driving directions

Clinical Trials


Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion

225 Candler Drive
Suite 300
Savannah, GA 31405
912-354-6187 (p)
www.summitcancercare.com

driving directions

Clinical Trials

Active Clinical Trial Site Locations:

**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.